X
Total 959151 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fronto-orbital gyrus | 'Fronto-orbital gyrus' is an orbital gyrus and frontal gyrus. It is part of the orbitofrontal cortex. | ILX:0104458 | 6 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Fronto-orbital sulcus | ILX:0104459 | 11 | FDI Lab - SciCrunch.org | 06/23/2020 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Frovatriptan | Frovatriptan (Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.(1) Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006(2) and which is currently pending.(3) The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM). Pharmacology: Frovatriptan is a second generation triptan 5-HT receptor agonist that binds with high affinity for 5-HT1B and 5-HT1D receptors. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Research has shown that migraine can be caused by the swelling of blood vessels around the brain. Frovatriptan eases the pain associated with migraine by narrowing these blood vessels. Frovatriptan has one of the highest affinities for the 5-HT1B of the second-generation triptan agonists. Mechanism of action: Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism. Drug type: Approved. Investigational. Small Molecule. Drug category: Anti-inflammatory Agents. Anti-migraine Agents. Serotonin Agonists. Vasoconstrictor Agents | ILX:0104460 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Frozen | A quality inhering in a bearer by virtue of being kept below its freezing point. | ILX:0104461 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| FRQS | The FRQS (Fonds de recherche du Québec - Santé) is a non-profit funding agency created under the Act Respecting the Ministère du Développement économique, de l'Innovation et de l'Exportation (L.R.Q., c. M-30.01).We report to the Minister in charge of Québec's department for economic development, innovation and export trade (ministère du Développement économique, de l'Innovation et de l'Exportation) and our mandate is to implement government strategy with respect to human health research as presented in the Québec Research and Innovation Strategy.The FRQS was established in 1964 by Québec's health department under the name Conseil de recherches médicales. A pioneer in both Québec and Canada, the FRQS advised the health minister in matters of medical research. Forty years later, the FRQS plays a leading role in planning and coordinating the development of health research in Québec.The FRQS allocates $100 million annually in awards and grants for public-sector research into human health carried out today in universities and hospital-based research centers. We fund projects using any of the recognized methodologies (basic, clinical, epidemiological, public health, health services and the social determinants of health). To fulfill our mission and maximize the economic and health benefits of scientific investigation, we invest in:*top-performing research investigators and students*research centers, groups and networks*excellence, innovation and the dissemination of knowledge*social responsibility and ethical practices*synergy and partnership | ILX:0104462 | 4 | FDI Lab - SciCrunch.org | 08/24/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| FSH receptor | ILX:0104463 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Full-spectrum EM radiation quality | An EM radiation quality that is independent of the EM wavelength range. | ILX:0104464 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Fulvestrant | Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. Pharmacology: Fulvestrant for intramuscular administration is an estrogen receptor antagonist without known agonist effects. Mechanism of action: Fulvestrant binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, when fulvestrant binds to the receptors, estrogen is crowded out and is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms prevent cancer cells from accessing sufficient amounts of estrogen needed for growth and replication. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Antineoplastic Agents, Hormonal. Estrogen Antagonists | ILX:0104465 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Function | ILX:0104466 | 3 | FDI Lab - SciCrunch.org | 06/12/2021 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Functional | A functionality quality which is an ability to perform a regular function(s). | ILX:0104467 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Functional Group Pointer | Contains the Data Element Tag of the Functional Group Sequence that contains the Attribute that is referenced by the Dimension Index Pointer (0020,9165). Required if the value of the Dimension Index Pointer (0020,9165) is the Data Element Tag of an Attribute. | ILX:0104468 | 4 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Functional Group Private Creator | Identification of the creator of a group of private data elements. | ILX:0104469 | 6 | FDI Lab - SciCrunch.org | 08/28/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Functional motor assessment | An assessment designed to test functional motor abilities | ILX:0104470 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Functional MRI assay | ILX:0104471 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Functional MRI platform | ILX:0104472 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Functional neuroimaging | Methods for visualizing REGIONAL BLOOD FLOW, metabolic, electrical, or other physiological activities in the CENTRAL NERVOUS SYSTEM using various imaging modalities. (MeSH) | ILX:0104473 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Functional part of brain | A brain region defined by functional criteria, e.g. auditory cortex, rather than by structural or histological criteria. | ILX:0104474 | 8 | FDI Lab - SciCrunch.org | 01/17/2023 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Functional role of cell | ILX:0104475 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Functional role of nerve cell | ILX:0104476 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Functionality | Quality of a single entity which is an ability or inability to perform a regular function(s). | ILX:0104477 | 3 | FDI Lab - SciCrunch.org | 06/18/2018 | FDI Lab - SciCrunch.org | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
The SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
Contact Us
FAIR Data Informatics Lab
University of California, San Diego
9500 Gilman Drive, Mail Code 0608
La Jolla, CA 92093-0608
United States
info 
scicrunch.org
scicrunch.org
X